This reflects in part the stringent criteria we used to report tumor types with >0.5-fold changes in mRNA expression compared to their normal counterparts, but also that the majority (>90%) of PARK2 deletions across all tumor types are heterozygous and, hence, less likely to cause a marked reduction in PARK2 mRNA expression. The gene discussed is PRKN; the disease is neoplasm.